Project Grant R43EY033591
Award Date
6/1/22
Completion Date
5/31/24
Dollars Obligated
$611K
Federal Agency
National Eye Institute
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
The National Eye Institute (NEI) awarded a $332,179 Project Grant (CFDA 93.867 Vision Research) to Diopter Technologies, Inc. to develop sustained-release contact lenses for delivering the drug cysteamine to treat the ocular complications of cystinosis. The project aims to create daily disposable contact lenses that can replace the current 8-times-daily cysteamine eye drop regimen. The contact lenses will utilize a patented nanobarrier technology to provide 2-8 hours of sustained cysteamine...
The National Eye Institute (NEI) awarded a $257,785 Project Grant (CFDA 93.867 Vision Research) to The Leland Stanford Junior University to develop a refillable, microfabricated lens capsule-based drug delivery device. The goal is to enable extended intraocular delivery of biologics, such as adalimumab, and immune-modulating peptides to treat non-infectious uveitis without the side effects of current therapies like cataracts or glaucoma. The project will characterize the in vitro and in vivo...
The National Eye Institute (NEI) awarded a $412,285 Project Grant under the Vision Research program (CFDA 93.867) to Oregon Health & Science University (OHSU) to validate an advanced transepithelial corneal collagen crosslinking (CXL) technology. The goal is to develop a more effective CXL procedure that can strengthen the cornea without requiring removal of the surface epithelium, which often leads to complications. The key products and services to be delivered include: Constructing an...
The National Eye Institute (NEI) awarded a $436,695 Project Grant (CFDA 93.867 Vision Research) to The Johns Hopkins University to develop a new eye drop-based treatment for neovascular age-related macular degeneration (NAMD) and other ocular diseases with neovascular complications. The grant supports the development and testing of a novel hypotonic gelling eye drop formulation designed to effectively deliver the HIF-1 inhibitor acriflavine to the posterior segment of the eye. Specific aims...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), will fund the development and testing of an intraocular projection system that can be implanted in the eye to restore vision for patients with severe corneal injuries or damage. The total award amount is $430,479.00 and the project will run from July 1, 2025 to June 30, 2030. The key products and services to be delivered under this grant include: Building and...
This $1,066,178 Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) supports the late-stage preclinical development and GMP production of a first-in-class extended release intraocular pressure (IOP)-lowering formulation for the treatment of glaucoma. The awardee, Tavo Biotherapeutics, Inc. (operating as Oculo Therapy LLC), is a woman-owned small business focused on developing innovative ophthalmic products. The funding will enable the company...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), supports the development of a safe and effective topical pharmacotherapy to treat acute corneal pain. The award of $590,172 to Vyluma Inc. aims to advance a topical formulation of pregabalin (NVK032) as a non-NSAID, non-steroid, and non-anesthetic treatment option. The key activities include: Pharmacodynamic dose identification studies in a rat model to determine the...
This $543,037 Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) supports research by New York University (NYU) School of Medicine on the development and function of corneal lens-secreting cells. The research aims to: Investigate the genetic mechanisms underlying cell differentiation in the retina that enable the formation of the corneal lens, which is critical for proper vision. Examine how the timing of cone and pigment cell...
The National Eye Institute (NEI) awarded a $247,500 Project Grant (CFDA 93.867 - Vision Research) to Trustees of Boston University's Medical Campus to investigate the role of limbal fibroblasts in maintaining limbal stem cells and develop a novel therapy for limbal stem cell deficiency (LSCD). The key objectives of this 2-year research project are to: 1) Reveal the characteristics of limbal fibroblasts and limbal dendritic cells; 2) Evaluate the interaction between limbal niche cells and...
The National Eye Institute (NEI) awarded a 4-year, $1,313,945 Project Grant (CFDA 93.867 - Vision Research) to the University of Arizona to develop a long-acting topical nanomedicine therapy for the treatment of ocular herpes simplex virus (HSV) infections. The project aims to repurpose and reformulate the drug adefovir dipivoxil (ADV) to improve its topical delivery and reduce dosing frequency compared to currently approved treatments. Key objectives include evaluating ADV solution versus...